com has published a recent study presented at the IAS2017 Conference in Paris revealing the following differences between countries in the
cost of hep-c meds:
"... the current lowest prices for a 12-week course of Sovaldi and Daklinza (daclatasvir) treatment for hep C range from a high of $142,710 in the United States to $104,723 in Denmark, $96,404 for treatment through Veterans Affairs in the United States, $50,059 in France, $29,361 in Brazil, $174 in Egypt and $108 in India.